NCT05649046

Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 160 (actual)
• Sponsor: Assistance Publique Hopitaux De Marseille · Academic / Other
• Sex: All
• Age: 45 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Patients treated at the Hôpital Nord de Marseille for at least one smoking-related pathology (atheroma, chronic bronchitis, non-progressive cancer \> 5 years) or with eligibility criteria for lung cancer screening (inclusion criteria in the NLST or NELSON studies or American recommendations) Interventional study with minimal risks and constraints, with evaluation of lung cancer prevalence; immunological, blood inflammatory and microbiota profile Determine the maximum clinical, radiological, and biological phenotyping completeness rate following the implementation of a new lung cancer screening care pathway with multidimensional clinical, radiological, and biological phenotyping capabilities

Conditions

• Smoking-related Pathology
• Atheroma
• Chronic Bronchitis
• Non-progressive Cancer > 5 Years
• Lung Cancer

Interventions

Type	Name	Description
DEVICE	thoracic scan Low dose	within 3 months after the V0 visit
BIOLOGICAL	BLOOD SAMPLE	within 3 months after the V0 visit
BIOLOGICAL	FECES SAMPLE	within 3 months after the V0 visit

Timeline

• Start date: 2023-01-23
• Primary completion: 2024-06-01
• Completion: 2024-06-01
• First posted: 2022-12-13
• Last updated: 2024-03-18

Locations

1 site across 1 country: France